Screening for atrial fibrillation in care homes using pulse palpation and the AliveCor Kardia Mobile® device: a comparative cross-sectional pilot study

Savickas, V. ORCID: https://orcid.org/0000-0002-8059-5619, Stewart, A. J., Short, V. J., Mathie, A., Bhamra, S. K., Veale, E. L. and Corlett, S. A. (2024) Screening for atrial fibrillation in care homes using pulse palpation and the AliveCor Kardia Mobile® device: a comparative cross-sectional pilot study. International Journal of Clinical Pharmacy, 46 (2). pp. 529-535. ISSN 2210-7703

[thumbnail of Savickas_etal_2024_IJCP]
Preview
PDF (Savickas_etal_2024_IJCP) - Published Version
Available under License Creative Commons Attribution.

Download (781kB) | Preview

Abstract

Background: Atrial fibrillation (AF) is a major cause of stroke in older people. Exacerbated by age and co-morbidities, residents of care homes are more likely to develop AF and less likely to receive oral anticoagulants. Aim: To determine the prevalence of AF using the design and methodology of the Pharmacists Detecting Atrial Fibrillation (PDAF) study in a care home setting. Method: A cross-sectional AF screening pilot study within four UK care homes, three residential and one residential/nursing. Screening followed the original PDAF protocol: a manual pulse check, followed by a single-Lead ECG (SLECG, AliveCor Kardia Mobile (KMD)) delivered by a pharmacist. All recorded SLECG were reviewed by a cardiologist and any residents requiring follow-up investigations were referred to their general practitioner. Results: Fifty-three of 112 care home residents participated. From 52 SLECGs recorded, the cardiologist interpreted 13.5% (7/52) as having possible AF of which 9.6% (5/52) were previously unknown. One resident with previously unknown AF received anticoagulation. Conclusion: This study has shown a need for AF screening in care homes and that elements of the PDAF screening protocol are transferable in this setting. Early diagnosis and treatment of AF are essential to reduce the risk of stroke in this population.

Item Type: Article
Additional Information: Funding information: This work was supported by a Medical Education Grant from Bayer UK (UKBAY09170342a) and a grant from the Kent, Surrey, and Sussex Community Education Providers Network (CEPN) for pharmacist training. The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Faculty \ School: Faculty of Science > School of Chemistry, Pharmacy and Pharmacology
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 21 Nov 2024 10:30
Last Modified: 27 Nov 2024 10:45
URI: https://ueaeprints.uea.ac.uk/id/eprint/97738
DOI: 10.1007/s11096-023-01672-z

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item